1 Plasma p-tau212 as a biomarker of sporadic and Down Syndrome Alzheimer's

2 disease

- 3
- 4 Przemysław R. Kac*, MSc¹, Daniel Alcolea*, MD, PhD^{2,3}, Laia Montoliu-Gaya, PhD¹, Susana
- 5 Fernández, MD¹⁴, Juan Lantero Rodriguez, PhD¹, Lucía Maure, MD^{2,3,14}, Fernando
- 6 González-Ortiz, MD^{1,4}, Bessy Benejam, PhD^{2,14}, Michael Turton, PhD⁵, Isabel Barroeta, MD
- 7 PhD^{2,3,14}, Peter Harrison, MA⁵, Laura Videla, PhD^{2,3,14}, Nicholas J. Ashton, PhD^{1,6,7,8}, Alberto
- 8 Lleó, MD PhD^{2,3}, Henrik Zetterberg, MD, PhD^{1,4,9,10,11,12}, María Carmona-Iragui, MD PhD^{2,3,14},
- 9 Thomas K. Karikari, PhD^{1,13}, Juan Fortea#, MD PhD^{2,3,14} and Kaj Blennow#, MD, PhD^{1,4,15,16}
- 10
- 11 ¹Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of
- 12 Gothenburg, Mölndal, Sweden,
- 13 ²Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de
- 14 Barcelona, Barcelona, Spain,
- 15 ³Center for Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain,
- 16 ⁴Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden,
- 17 ⁵Bioventix Plc, Farnham, GU9 7SX, United Kingdom,
- 18 ⁶Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway,
- 19 ⁷NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS
- 20 Foundation, London, United Kingdom,
- 21 ⁸Department of Old Age Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, London,
- 22 United Kingdom,
- 23 ⁹Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of
- 24 Wisconsin-Madison, Madison, WI, USA,
- 25 ¹⁰Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China, ¹¹Department of Neurodegenerative
- 26 Disease, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom,
- 27 ¹²UK Dementia Research Institute at UCL, London, United Kingdom,
- 28 ¹³Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA,
- 29 ¹⁴Barcelona Down Medical Center, Fundació Catalana Síndrome de Down, Barcelona, Spain
- 30 ¹⁵Paris Brain Institute, ICM, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France
- 31 ¹⁶Neurodegenerative Disorder Research Center, Division of Life Sciences and Medicine, and Department of Neurology, Institute on
- 32 Aging and Brain Disorders, University of Science and Technology of China and First Affiliated Hospital of USTC, Hefei, P.R. China
- 33 *Przemysław R. Kac and Daniel Alcolea contributed equally as first authors
- 34 #Kaj Blennow and Juan Fortea contributed equally as senior authors

35 Abstract

36 Background

37 All individuals with Down Syndrome (DS) will develop full-blown Alzheimer's disease (AD) 38 pathology by age 40, decades before the occurrence of sporadic late-onset AD. 39 Understanding this strong biological relation between age and AD pathology risk in DS is 40 important to accelerate diagnostics, disease monitoring, and treatment. Several genes 41 encoded in chromosome 21 including dual-specificity tyrosine phosphorylation-regulated 42 kinase 1A (DYRK1A) have been proven to contribute to the pathology. A recently validated 43 plasma immunoassay to measure tau phosphorylation at threonine-212 (p-tau212) has very 44 high diagnostic accuracy in detecting AD. P-tau212 is also very sensitive to DYRK1A 45 phosphorylation and is increased in DSAD brain lysates. Here, we assessed the potential of 46 this biomarker in DSAD and sporadic AD.

47 Methods

Using Simoa technology, we tested p-tau212 and p-tau181 (n=245 for plasma, n=114 matching cerebrospinal fluid (CSF) samples). We used AUC-ROC to examine diagnostic performance and the DeLong test to compare the AUC-ROC differences between methods. Spearman correlation is used to examine correlations. Fold changes relative to median levels were calculated for their respective asymptomatic groups. ANCOVA followed by Tukey posthoc test was used to calculate differences across groups. LOESS was used to determine the temporality of plasma biomarker changes.

55 Results

We have confirmed that p-tau212 has extremely high accuracy in detecting AD-related changes in euploid controls. For the DS population, we observed a strong correlation between plasma and CSF p-tau212 (r=0.867; p<0.001). In prodromal DS (pDS) and dementia DS (dDS), we observed significantly elevated levels of p-tau212 in reference to

60	asymptomatic DS (aDS). The diagnostic accuracy to differentiate between aDS and dDS was
61	AUC=0.91 and AUC = 0.86 in discriminating between DS amyloid positive and amyloid
62	negative participants. Plasma p-tau212 started increasing approximately when people
63	became amyloid PET-positive.
64	Conclusions
65	We have confirmed that the levels of plasma p-tau212 are increased in the DS population
66	and sporadic AD cases including prodromal and MCI states. Plasma p-tau212 might have
67	utility for theragnostic, monitoring therapy efficacy, and as a target engagement biomarker in

69

70 Keywords

Alzheimer's disease; Down Syndrome; plasma biomarkers; p-tau212; DYRK1A; DABNI;
 SPIN; Simoa; CSF biomarkers.

73

74 Introduction

75 A triplication of chromosome 21 causes Down syndrome (DS)(1). All individuals with DS 76 develop full-blown Alzheimer's Disease (AD) pathology by age 40(2) and the lifetime risk of 77 developing AD exceeds 90% in the seventh decade(3). The estimated age of onset of AD 78 dementia in this population is 53.8 years, decades before the occurrence of late-onset AD in 79 the general population(4). Understanding this strong DSAD relationship is important to 80 accelerate diagnostics and treatment. This ultra-high risk is mainly due to the triplication of 81 the amyloid precursor protein (APP), which leads to the overproduction of amyloid- β (A β) 82 peptides, and increased Aß plaques formation(5). Although other genes encoded in 83 chromosome 21 such as dual-specificity tyrosine phosphorylation-regulated kinase 1A 84 (DYRK1A) and RCAN1 contribute to the pathology(6-9). DYRK1A is a dose-sensitive gene

that overexpression contributes to DS cognitive dysfunction(10). This protein phosphorylates
different targets involved in AD development and progression for instance Glycogen
synthase kinase-3β (GSK-3β)(11), Presenilin1(12), APP(6), and tau(13).

88

89 Diagnosing DSAD is challenging due to the association of DS with cognitive 90 dysfunction(14,15). Recent advances allow us to recognize ante-mortem AD pathology using 91 blood-based biomarkers(16-19). These reflect the disease almost as accurately as more 92 expensive and less available CSF and imaging biomarkers(20). Several plasma p-tau 93 biomarkers have been found to reflect both A β and tau pathology(21). Recently validated 94 plasma p-tau212 has shown very high performance for detecting those pathologies and AD 95 diagnosis(22). That phosphorylation site might also have the strongest biological correlation 96 with AD pathology in DS since threonine-212 is a primary target for DYRK1A in tau 97 protein(23). Intensified phosphorylation at thr-212 induces tau aggregation, reduces tau 98 binding to microtubules, and increases cell toxicity in in-vitro studies(24). Levels of p-tau212 99 are highly elevated in reference to AD and control participants in human AD-DS brains(25). 100 Additionally, a major tau phosphatase – Protein phosphatase 1A (PP1A) is not 101 dephosphorylating p-tau212 derived from AD brains(26), suggesting that this epitope might 102 be vulnerable to very subtle changes related to AD pathology. Knowing that direct biological 103 association, we hypothesized that p-tau212 is an accurate tau species to reflect AD 104 pathology in the DS population. To test this hypothesis, we used Single molecule array 105 (Simoa) immunoassays to measure plasma and cerebrospinal fluid (CSF) p-tau212 106 concentrations in asymptomatic DS (aDS), prodromal DS (pDS), and dementia DS (dDS) 107 individuals, as well as in sporadic AD patients both in Mild Cognitive impairment (MCI) and 108 dementia states and we compare the results with a validated biomarker.

109

110

111

112

113 Methods

114 Study design and participants

115 We performed a cross-sectional cohort study of adults with DS, and euploid individuals along 116 the Alzheimer's disease continuum in the Hospital of Sant Pau, Barcelona (Spain), Adults 117 with DS in Barcelona were recruited from a population-based health plan designed to screen 118 for AD dementia, which includes yearly neurological and neuropsychological assessments. 119 Those subjects interested in research studies are included in the Down Alzheimer Barcelona 120 Neuroimaging Initiative (DABNI) cohort(14,15). We also recruited euploid controls and 121 sporadic Alzheimer's disease patients from the Sant Pau Initiative on Neurodegeneration 122 (SPIN cohort)(27).

123

124 Biomarker measurements

Amyloid-β peptides (Aβ40, Aβ42) analyses were performed on the LUMIPULSE G600II, and 125 126 the cut-off for positivity was defined as in the previous publication(28). All other plasma and 127 CSF biomarker assays were performed on the Simoa HD-X platform at the University of 128 Gothenburg. P-tau212 and p-tau181 concentrations were measured using published and 129 validated in-house assays(16,22). For p-tau181, the AT270 antibody (Invitrogen) was used 130 as a capture antibody and was paired with n-terminal antibody for detection (Tau12; 131 BioLegend). For p-tau212, a sheep monoclonal antibody was used for capture paired with 132 Tau12 as the detector. Coefficients of variation for 3 different internal quality controls for 133 plasma were 5.3-12% for within-plate variation and 6.4%-12% for between-plate variation. 134 For CSF, these values were 10.8%-13.3% and 12.9%-15.5%, respectively.

135

136 Statistical Analysis:

We used AUC-ROC to examine diagnostic performance and the DeLong test to compare the
 AUC-ROC differences between methods. Spearman correlation is used to examine

correlations. Fold changes relative to median levels are calculated for their respective asymptomatic groups. Age-adjusted analysis of covariance (ANCOVA) followed by Tukey post-hoc test is used to calculate differences across groups. A First-degree locally estimated scatterplot smoothing curve (LOESS) is independently used in controls and adults with Down Syndrome to determine the temporality of plasma biomarker changes. For Down participants we set the mean age of symptoms onset at 53.8 years according to a previous study from our group(29). All significance tests were two-sided, and significance was set at p<0.05.

146

147 **Results**

148 Cohort characteristics

We tested n=245 plasma samples for p-tau212 and p-tau181. A subset of participants had amyloid PET data. Table 1. shows the demographics, cognitive, and plasma biomarkers across groups of all participants included in the analyses. N=114 (47%) participants had CSF biomarker measurements. Demographics for the CSF subset are shown in Supplementary Table 1.

154

155 Correlations with biomarkers and cognition

156 Plasma and CSF p-tau212 were highly correlated with each other within the cohort. We 157 observed moderate correlation across sample types in all participants (r=0.712 p<0.0001) 158 (Fig. 1A). However, the strongest correlation of plasma p-tau212 with CSF p-tau212 was 159 observed in the DS-only subgroup (r=0.867, p<0.0001) (Fig 1A). This improved CSF-plasma 160 correlation in DS groups was not seen for p-tau181, which showed similar correlations in the 161 whole cohort and subgroups (r=0.652-0.681, p<0.0001) (Fig 1B). Those results indicate that 162 plasma p-tau212 measurements accurately reflect AD-related p-tau level changes in CSF in 163 sporadic and DS groups.

164

Figure 1. Spearman correlations for plasma and CSF p-tau212 and p-tau181. The Figure shows correlations between plasma and CSF for **A**) p-tau212 and **B**) p-tau181 for euploid groups (n=88; p<0.001; r= 0.701 and r=0.660 respectively) and DS groups (n=26, p<0.001; r=0.867, r=0,681 respectively). The correlation between plasma and CSF measurements for all measurements (n=114, p<0.001) is 0.712 for p-tau212 and 0.652 for p-tau181. The fitted simple linear regression line is presented as a mean and error.

Both biomarkers were correlated with decrease in The Cambridge Cognitive Examination adapted for individuals with Down Syndrome (CAMCOG-DS) in plasma (r=-0.338; p=0.001 for p-tau212 and r=-0.328 for p-tau181; p=0.002;) and in CSF (r=-0.686; p<0.001 for p-

175 tau212; and r=-0.511; p<0.001 for p-tau181).

176

171

177 Plasma p-tau212 levels are increased in asymptomatic Down syndrome

Plasma p-tau212 concentration was 2.4x times higher in the aDS group compared with cognitively normal (CN) euploid people (p<0.001) whereas plasma p-tau181 was not significantly changed (p=0.052).

181

182 Plasma and CSF p-tau212 increase along the AD continuum in DSAD and sporadic AD

183 Both in individuals with DS and euploid participants, p-tau212 levels were increased in 184 symptomatic patients in comparison with asymptomatic individuals. (Fig. 2A). For pDS we 185 observed a 3.4x (p=0.003) mean fold increase in plasma and a 5.6x mean fold-fold increase 186 in CSF in reference to aDS. For dDS we observed a 2.9x (p=0.004) mean fold increase in 187 plasma and a 7.1x mean fold increase in CSF. For MCI-AD, compared with cognitively 188 normal euploid people, we observed a 3.0x (p<0.001) mean fold increase in plasma and a 189 7.8x mean fold increase in CSF. AD dementia patients had a 3.8x mean fold increase in 190 plasma (p<0.001) and a 9.1x mean fold increase in CSF. P-tau181 concentrations were also 191 increased, but with a lower magnitude than p-tau212, and comparison between DS groups 192 showed no significance (Fig. 2B). Both biomarkers kept the pattern of greater increases in 193 CSF than in plasma (Supplementary Fig. 1A-B).

194

Figure 2. Plasma p-tau212 and p-tau181 levels in euploid and Down Syndrome (DS) groups. Box plots represent median and IQR, and boundaries of the whiskers are minimum to maximum values for A) plasma p-tau212 and B) plasma p-tau181. Differences for euploid

participants are calculated for Mild Cognitively impaired Alzheimer's Disease (MCI-AD; n=62) and Alzheimer's Disease Dementia (AD; n=20) in reference to Cognitively Normal (CN; n=46) participants. Differences for prodromal Alzheimer's Disease in DS (pDS; n=8) and Alzheimer's Disease dementia in DS (dDS; n=17) are calculated in reference to asymptomatic (aDS; n=92). Age-adjusted analysis of covariance (ANCOVA) followed by Tukey post-hoc test is used to calculate differences across groups.

204

205 Plasma p-tau212 has greater diagnostic accuracy than p-tau181

206 ROC analysis was used to evaluate the diagnostic performance of plasma and CSF p-tau212 207 and p-tau181. AUCs were usually higher for biomarkers in CSF, and for p-tau212 than for p-208 tau181. In our comparisons, we included Age+ Apolipoprotein E4 (APOE4)+Sex since they 209 have been shown to influence diagnostic accuracy(30). AUCs of Age+APOE+Sex were not 210 significantly different from p-tau212 but better than p-tau181. Both biomarkers had high 211 accuracy to differentiate between CN and AD in plasma AUC = 0.96 (95% CI 0.92-1) for p-212 tau212 and AUC = 0.89 (95% CI 0.84-0.95) for p-tau181 (Fig. 3B). For differentiating between CN and MCI-AD (Fig. 3A) or MCI-AD+AD (Fig. 3C), p-tau212 had accuracy of 0.91 213 214 (95% CI 0.85-0.97) and AUC=0.93 [95% CI 0.88-0.97] respectively. That accuracy was 215 significantly higher than p-tau181 - (p=0.026 for both comparisons). Plasma p-tau212 216 reached AUC=0.91 (95% CI 0.86-0.97) to differentiate between aDS and dDS diagnosis (Fig.

217 3D).

218

219 Figure 3. Diagnostic accuracy of plasma and CSF biomarkers to discriminate between 220 sporadic and DSAD groups. P-tau212 and p-tau181 receiver operating characteristic 221 curves (ROC) to discriminate between sporadic and DSAD groups. Plasma p-tau181, plasma 222 p-tau212, CSF p-tau181, CSF p-tau212, and Age+APOE+Sex are on each graph. In A) ROC 223 curves for differentiating Cognitively normal (CN) and Mild Cognitive Impairment -Alzheimer's Dementia (MCI-AD). B) ROC curves to discriminate between CN and 224 225 Alzheimer's Disease (AD). C) ROC curves to differentiate between CN and MCI-AD 226 combined with AD group. D) ROC curves to discriminate between asymptomatic Down 227 syndrome (aDS) and prodromal Down Syndrome (pDS) + dementia Down syndrome (dDS). 228

229 Plasma p-tau212 increases approximately parallel to amyloid PET positivity and has

230 great accuracy in discriminating between $A\beta$ + and $A\beta$ - participants

231 Both biomarkers had significant accuracy in discriminating between Aβ+ and Aβ- participants

232 (Fig. 4). Plasma p-tau212 had numerically higher accuracy than p-tau181 both for DS (AUC

233 = 0.86 (95% CI = 0.7-1) (Fig. 4B) and euploid participants AUC = 0.9 (0.83 - 0.96) (Fig. 4C).

234

Figure 4. Diagnostic accuracy of plasma and CSF biomarkers to discriminate between A β + and A β - participants. P-tau212 and p-tau181 receiver operating characteristic curves (ROC) to discriminate between amyloid positive (A β +) and amyloid negative (A β -) participants in sporadic and DSAD groups. Plasma p-tau181, plasma p-tau212, CSF ptau181, CSF p-tau212, and Age+APOE+Sex are on each graph. In **A**) ROC curves for differentiating A β + from A β - in whole cohort. **B**) ROC curves to discriminate A β + and A β - in DS groups. **C**) ROC curves to differentiate between A β + and A β - in euploid groups.

242

An early increase in plasma levels was observed many years before the onset of clinical AD

symptoms in DS (Fig 5). For p-tau212 the increase started approximately when people

became amyloid PET-positive, *i.e.*, in their late 30s, and approximately 15 years before the

disease onset (Fig. 5A). P-tau181 started increasing approximately 10 years before the

- 247 estimated disease onset (Fig. 5B).
- 248

Figure 5. Age-related plasma p-tau212 and p-tau181 changes in Down syndrome and euploid controls. Open Circles represent asymptomatic and filled circles represent symptomatic participants. Down syndrome population is represented in red and cognitively normal euploid people are represented in blue. Horizontal lines depict each group's fitted loess model, and fainted bands display confidence intervals. The vertical red line represents the estimated years to symptom onset which is 53.8 for Down syndrome participants and was used as reference in euploid controls for comparison purposes.

257 **Discussion**

In this cross-sectional study, we show that p-tau212 serves as a biomarker to track AD-

related changes in sporadic cases and DSAD. P-tau212 has a very high correlation between

260 plasma and CSF. The strongest correlation was observed for the DS population, where p-

tau212 reached a greater correlation than for euploid participants. For p-tau181 correlation in

262 euploid and DS groups was similar, suggesting greater translation from CSF to plasma for p-

tau212 in DS populations.

We observed elevated p-tau212 concentration in plasma and CSF in aDS compared with euploid CN. That elevation is greater than the p-tau181 elevation, which did not reach statistical significance. Additionally, other reported biomarkers, such as p-tau217 Glial fibrillary acidic protein (GFAP)(30,31), had lower increases. This suggests the effects of DYRK1A gene dose interacting with AD pathology on p-tau212 levels in DS and a better fit for the use of this biomarker in the DS population.

271

Levels of plasma p-tau212 were significantly higher across disease groups. Plasma p-tau212 reached significance levels to differentiate between aDS vs pDS and aDS vs dDS groups while p-tau181 failed to do it. However, we think this might be a limitation of the small sample size used in this cohort since p-tau181 levels were previously shown to be significantly increased in pDS and aDS(30,32). In MCI-AD and AD dementia groups, we observed significant increases for both biomarkers, concomitantly having fold changes higher for ptau212 which confirms our previous findings(22).

279

280 The excellent performance of the assay was confirmed in discriminating patients according to 281 the diagnosis in both DS and euploid groups. P-tau212 additionally has greater accuracy 282 than p-tau181 in discriminating between MCI-AD and control groups, simultaneously 283 reaching 0.96 AUC to differentiate CN from AD. Additionally, plasma p-tau212 acquired very 284 high AUC-ROC in discriminating between A β + and A β - participants in both euploid and DS 285 groups. This accuracy was not different from CSF accuracy, supporting the high between-286 matrix translation of p-tau212 and providing additional reasoning to use plasma p-tau212 to 287 recruit participants for clinical trials.

288

Plasma p-tau212 starts increasing in the 30s, approximately when people start being positive in amyloid PET scans, and 5 years before we observe an increase in p-tau181. Additionally, the biomarker increased further as AD progressed towards symptomatic stages. Therefore ptau212 could be useful to monitor the progression of asymptomatic DS people to prodromal

AD. Moreover, the onset of the increase comes along with the appearance of neurofibrillary
 tangles (NFTs) and Aβ plagues in brain(4,33).

295

296 This is (to our best knowledge) the first study to measure p-tau212 in CSF and plasma as a 297 biomarker for DSAD however, the potential involvement of p-tau212 in this population and its 298 association with DYRK1A was published more than 20 years ago(13). The kinase is 299 perceived as a target in DS and neurodegenerative diseases(8,34). Its under- or 300 overexpression leads to different clinical phenotypes including cognitive impairment(34). 301 Since DYRK1A is a dose-sensitive protein in which down-regulation or up-regulation has a 302 critical role. DYRK1A inhibitors have already been widely explored in clinical trials and have 303 been proven to improve cognitive function in DS people(10.35,36). Importantly, p-tau212 has 304 already been successfully used to test the efficacy of DYRK1A inhibitor in cell models(37). 305 The use of the chosen inhibitor was further shown to reverse the upregulation of p-tau212 in 306 hippocampal tissue and temporal cortex in mouse models(37). Our novel plasma p-tau212 307 immunoassay provides a simple-to-implement and cost-effective opportunity to monitor the 308 efficacy of DYRK1A inhibitors, or in the future – enhancers, not allowing the activity of this 309 kinase to be reduced or increased to levels that could cause more harm than good. This 310 utility will be explored in our future research.

311

312 The major strength of this study is the confirmation that p-tau212 is increased in the DS 313 population, and levels of this biomarker increase with progression to AD dementia. P-tau212 314 reaches very high accuracy to differentiate between control and disease groups and Aβ+ and 315 Aβ- participants. The high correlation between plasma and CSF p-tau212 also supports a 316 very high translation of the results from CSF to plasma. DeLong tests between DS groups 317 did not show any significantly better performance of CSF p-tau212 compared with plasma p-318 tau212 providing further evidence that plasma measurements can be used for clinical 319 evaluation of AD pathophysiological processes occurring in patients with suspected disease. 320 Advantages would also be reflected in the economy, availability, and perception of the test,

since lumbar punctures or PET scans are costly, require resources, and might be perceived
as frightening(20). Next, plasma p-tau212 increased approximately when people are starting
to be amyloid PET positive and 5 years before p-tau181, indicating the benefits in disease
monitoring.

325

This study has a few limitations. First is a slightly low representation of prodromal-DS participants, which prohibits us from making better AUC-ROC analysis in that group. Ideally, longitudinal measurements of p-tau212 in the DS population would tell us more about the trajectories of this biomarker. The second limitation is that p-tau217 measurements are unavailable at the moment, however direct comparison between biomarkers was not a purpose of experiments presented in this article. Still, p-tau181 is the most commercialized and fully automated immunoassay, with great utility in AD.

333

334 Conclusions

335 In conclusion, we have confirmed that levels of plasma p-tau212 are increased in the DS 336 population and sporadic AD cases including prodromal and MCI states. High accuracy in 337 discriminating amyloid positive from amyloid negative people and increase in parallel to 338 amyloid-PET positivity give the promise to evaluate ongoing pathophysiological AD 339 processes many years before the disease onset in individuals with DS. This will also facilitate 340 participants recrutation for clinical trials. This is a cost-effective application that provides 341 higher chance to receive appropriate therapy. Plasma p-tau212 will also find high utility for 342 theragnostic, to monitor therapy efficacy, and as a target engagement biomarker in clinical 343 trials both in sporadic and DSAD.

344

345 **Abbreviations**

346 AD: Alzheimer's disease

- 347 DS: Down Syndrome
- 348 DYRK1A: dual-specificity tyrosine phosphorylation-regulated kinase 1A
- 349 p-tauX: tau phosphorylated at amino acid X
- 350 DSAD Down Syndrome Alzheimer's disease
- 351 CSF Cerebrospinal Fluid
- 352 AUC-ROC: Area Under the Curve and Receiver Operating Curves
- 353 ANCOVA: Age-adjusted analysis of covariance
- 354 LOESS: locally estimated scatterplot smoothing
- 355 pDS: prodromal Down syndrome
- 356 aDS: asymptomatic Down syndrome
- 357 dDS: dementia Down syndrome
- 358 PET: Positron Emission Tomography
- 359 MCI: mild cognitive impairment
- 360 Aβ: amyloid beta
- 361 APP: amyloid precursor protein
- 362 GSK-3β: Glycogen synthase kinase-3β
- 363 PP1A: Protein phosphatase 1A
- 364 DABNI: Down Alzheimer Barcelona Neuroimaging Initiative
- 365 SPIN: Sant Pau Initiative on Neurodegeneration

- 366 CN: cognitively normal
- 367 IQR; interquartile range
- 368 SD: standard deviation
- 369 CAMCOG-DS: The Cambridge Cognitive Examination adapted for individuals with Down
- 370 Syndrome
- 371 APOE4: Apolipoprotein E4
- 372 GFAP: Glial fibrillary acidic protein
- 373 NFTs: Neurofibrillary tangles

374

375 **Declarations**

376 Ethics approval and consent to participate

377 Study procedures were approved by the Sant Pau Ethics Committee (IIBSP-NGF-2018-36 378 and IIBSP-DOW-2014-30), following the standards for medical research in humans, as 379 recommended in the Declaration of Helsinki. All participants or their legally authorized 380 representative gave written informed consent before enrolment.

381

382 Consent for publication

383 Not applicable

384

385 Availability of data and materials

386 Blinded Anonymized data is available on reasonable request from the corresponding author.

387 Request will be reviewed by the investigators and respective institutions to verify if data

- transfer is in the agreement with EU legislation on the general data protection or is subject to
- 389 any intellectual property or confidentiality obligations.

390

391 Competing interests

392 MT and PH are employees of Bioventix Plc. HZ has served at scientific advisory boards 393 and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, 394 Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, 395 LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon 396 Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens 397 Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by 398 Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder 399 of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures 400 Incubator Program (outside submitted work). KB has served as a consultant or at advisory 401 boards for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, 402 Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB, a 403 404 GU Ventures-based platform company at the University of Gothenburg. D.A. participated in 405 advisory boards from Fujirebio-Europe, Roche Diagnostics, Grifols S.A. and Lilly, and 406 received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka 407 Farmacéutica S.L., Zambon S.A.U. and Esteve Pharmaceuticals S.A. D.A. and JF declare a 408 filed patent application (licensed to Adx, EPI8382175 J.F. reported receiving personal fees 409 for service on the advisory boards, adjudication committees or speaker honoraria from AC 410 Immune, Adamed, Alzheon, Biogen, Eisai, Esteve, Eisai, Fujirebio, Ionis, Laboratorios 411 Carnot, Lilly, Life Molecular Imaging, Lundbeck, Perha, Roche, and, outside the submitted 412 work. The other authors declare no competing interest.

413

414 Funding

PRK was funded by Demensförbundet and Anna Lisa and Brother Björnsson's Foundation.
LMG is supported by the Brightfocus Foundation (A2022015F), the Swedish Dementia

417 Foundation, Gun and Bertil Stohnes Foundation, Ahlén-stifelsen, Alzheimerfonden (AF-418 968621) and Gamla Tjänarinnor Foundation. FG-O was funded by the Anna Lisa and Brother 419 Björnsson's Foundation. HZ is a Wallenberg Scholar and a Distinguished Professor at the 420 Swedish Research Council supported by grants from the Swedish Research Council (#2023-421 00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and 422 innovation programme under grant agreement No 101053962, Swedish State Support for 423 Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), 424 USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-425 21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the 426 Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson 427 Family Foundation, Familjen Rönströms Stiftelse, Stiftelsen för Gamla Tjänarinnor, 428 Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and 429 innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 430 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research 431 (JPND2021-00694), the National Institute for Health and Care Research University College 432 London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at 433 UCL (UKDRI-1003). KB is supported by the Swedish Research Council (#2017-00915 and 434 #2022-00732), the Swedish Alzheimer Foundation (#AF-930351, #AF-939721, #AF-968270, 435 and #AF-994551), Hjärnfonden, Sweden (#FO2017-0243 and #ALZ2022-0006), the Swedish 436 state under the agreement between the Swedish government and the County Councils, the 437 ALF-agreement (#ALFGBG-715986 and #ALFGBG-965240), the European Union Joint 438 Program for Neurodegenerative Disorders (JPND2019-466-236), the Alzheimer's Association 439 2021 Zenith Award (ZEN-21-848495), the Alzheimer's Association 2022-2025 Grant (SG-23-440 1038904 QC), La Fondation Recherche Alzheimer (FRA), Paris, France, the Kirsten and 441 Freddy Johansen Foundation, Copenhagen, Denmark, and Familjen Rönströms Stiftelse, 442 Stockholm, Sweden. TKK was supported by the NIH (R01 AG083874, RF1 AG052525-01, 443 P30 AG066468-04, R01 AG053952, R01 MH121619, R37 AG023651, RF1 AG025516-12A1, 444 R01 AG073267, R01 MH108509, R01 AG075336, R01 AG072641, P01 AG025204), the

445 Swedish Research Council (Vetenskåpradet; #2021-03244), the Alzheimer's Association 446 (#AARF-21-850325), the Swedish Alzheimer Foundation (Alzheimerfonden), the Aina (Ann) 447 Wallströms and Mary-Ann Sjöbloms stiftelsen, and the Emil och Wera Cornells stiftelsen. J.F 448 was supported by the Fondo de Investigaciones Sanitario, Carlos III Health Institute 449 (INT21/00073, PI20/01473 and PI23/01786) and the Centro de Investigación Biomédica en 450 Red sobre Enfermedades Neurodegenerativas Program 1, partly jointly funded by Fondo 451 Europeo de Desarrollo Regional, Unión Europea, Una Manera de Hacer Europa. This work 452 was also supported by the National Institutes of Health grants (R01 AG056850; R21 453 AG056974, R01 AG061566, R01 AG081394 and R61AG066543), the Department de Salut 454 de la Generalitat de Catalunya. Pla Estratègic de Recerca i Innovació en Salut (SLT006/17/00119). It was also supported by Fundación Tatiana Pérez de Guzmán el Bueno 455 456 (IIBSP-DOW-2020-151) and Horizon 2020–Research and Innovation Framework Programme 457 from the European Union (H2020-SC1-BHC-2018-2020).

458

459 Authors' contributions

PRK, DA, NJA, HZ, TKK, JF and KB created the concept and design. Data acquisition and
analysis was performed by PRK, DA, LMG, JLR, NJA, JF. SF, LM, BB, MT, IB, PH, LV, AL,
MC-I contributed to the sample selection/and or interpretation of the data. PKK, DA, LMG,
JLR, FG-O, HZ, TKK, JF and KB drafted the manuscript, and all authors revised. All authors
read and approved the final manuscript.

465

466 Acknowledgements

We thank all the participants with Down syndrome, their families, and their carers for their support of, and dedication to this research. We also acknowledge Fundació Catalana Síndrome de Down for global support and the members of the Alzheimer Down Unit and the Memory Unit from Hospital de la Santa Creu i Sant Pau for their daily work and dedication.

471

472 References

473	1.	Lejeune J, Gautier M, Turpin R. [Study of somatic chromosomes from 9 mongoloid
474		children]. Comptes Rendus Hebd Seances Acad Sci. 1959 Mar 16;248(11):1721–2.
475	2.	Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and
476		dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985;17(3):278-82.
477	3.	McCarron M, McCallion P, Reilly E, Dunne P, Carroll R, Mulryan N. A prospective 20-
478		year longitudinal follow-up of dementia in persons with Down syndrome. J Intellect
479		Disabil Res. 2017;61(9):843–52.
480	4.	Fortea J, Zaman SH, Hartley S, Rafii MS, Head E, Carmona-Iragui M. Down syndrome-
481		associated Alzheimer's disease: a genetic form of dementia. Lancet Neurol. 2021
482		Nov;20(11):930–42.
483	5.	Ballard C, Mobley W, Hardy J, Williams G, Corbett A. Dementia in Down's syndrome.
484		Lancet Neurol. 2016 May 1;15(6):622–36.
485	6.	Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H, et al. The DYRK1A gene,
486		encoded in chromosome 21 Down syndrome critical region, bridges between beta-
487		amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet. 2007
488		Jan 1;16(1):15–23.
489	7.	Branca C, Shaw DM, Belfiore R, Gokhale V, Shaw AY, Foley C, et al. Dyrk1 inhibition
490		improves Alzheimer's disease-like pathology. Aging Cell. 2017 Oct;16(5):1146–54.
491	8.	Wegiel J, Kaczmarski W, Barua M, Kuchna I, Nowicki K, Wang KC, et al. Link between
492		DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration
493		with 3-repeat tau protein in Down syndrome. J Neuropathol Exp Neurol. 2011
494		Jan;70(1):36–50.
495	9.	Ermak G, Harris CD, Battocchio D, Davies KJA. RCAN1 (DSCR1 or Adapt78) stimulates

496 expression of GSK-3beta. FEBS J. 2006 May;273(10):2100–9.

497	10. Duchon A,	Herault Y.	DYRK1A, a	a Dosade-S	Sensitive	Gene	Involved in

- 498 Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.
- 499 Front Behav Neurosci [Internet]. 2016 [cited 2021 Jul 14];10. Available from:
- 500 https://www.frontiersin.org/articles/10.3389/fnbeh.2016.00104/full#B228
- 501 11. Skurat AV, Dietrich AD. Phosphorylation of Ser640 in muscle glycogen synthase by
- 502 DYRK family protein kinases. J Biol Chem. 2004 Jan 23;279(4):2490–8.
- 12. Ryu YS, Park SY, Jung MS, Yoon SH, Kwen MY, Lee SY, et al. Dyrk1A-mediated
- 504 phosphorylation of Presenilin 1: a functional link between Down syndrome and
- 505 Alzheimer's disease. J Neurochem. 2010;115(3):574–84.
- 13. Woods YL, Cohen P, Becker W, Jakes R, Goedert M, Wang X, et al. The kinase DYRK
- 507 phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the
- 508 microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen

synthase kinase 3-priming kinase. Biochem J. 2001 May 1;355(Pt 3):609–15.

- 510 14. Fortea J, Carmona-Iragui M, Benejam B, Fernández S, Videla L, Barroeta I, et al. Plasma
- and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down
- 512 syndrome: a cross-sectional study. Lancet Neurol. 2018 Oct 1;17(10):860–9.
- 513 15. Fortea J, Vilaplana E, Carmona-Iragui M, Benejam B, Videla L, Barroeta I, et al. Clinical
- and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-

sectional study. The Lancet. 2020 Jun 27;395(10242):1988–97.

- 16. Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood
- 517 phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic
- 518 performance and prediction modelling study using data from four prospective cohorts.
- 519 Lancet Neurol. 2020 May;19(5):422–33.

520 17. Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, e	520	17. Palmq	vist S. Jane	lidze S. Qu	iroz YT.	Zetterberg I	H, Lo	pera F.	Stomrud E	. et	al.
---	-----	-----------	--------------	-------------	----------	--------------	-------	---------	-----------	------	-----

- 521 Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other
- 522 Neurodegenerative Disorders. JAMA. 2020 Aug 25;324(8):772–81.
- 18. Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et
- 524 al. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta
- 525 Neuropathol (Berl). 2021 May 1;141(5):709–24.
- 526 19. Kac PR, Gonzalez-Ortiz F, Simrén J, Dewit N, Vanmechelen E, Zetterberg H, et al.
- 527 Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease.
- 528 Alzheimers Res Ther. 2022 May 11;14(1):65.
- 529 20. Gonzalez-Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, Karikari TK. Plasma
- 530 phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial
- applications. Mol Neurodegener. 2023 Mar 16;18(1):18.
- 532 21. Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE, et al.
- 533 Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of
- amyloid with tau. EMBO Mol Med. 2021 Jun 8;13(6):e14022.
- 535 22. Kac PR, González-Ortiz F, Emeršič A, Dulewicz M, Koutarapu S, Turton M, et al. Plasma
- p-tau212 antemortem diagnostic performance and prediction of autopsy verification of
- 537 Alzheimer's disease neuropathology. Nat Commun. 2024 Mar 23;15(1):2615.
- 538 23. Liu F, Liang Z, Wegiel J, Hwang YW, Iqbal K, Grundke-Iqbal I, et al. Overexpression of
 539 Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J. 2008
 540 Sep;22(9):3224–33.
- 541 24. Alonso AD, Di Clerico J, Li B, Corbo CP, Alaniz ME, Grundke-Iqbal I, et al.
- 542 Phosphorylation of Tau at Thr212, Thr231, and Ser262 Combined Causes
- 543 Neurodegeneration. J Biol Chem. 2010 Oct 1;285(40):30851–60.

544	25. Sawa M, Overk C, Becker A, Derse D, Albay R, Weldy K, et al. Impact of increased APP
545	gene dose in Down syndrome and the Dp16 mouse model. Alzheimers Dement.
546	2022;18(6):1203–34.

- 547 26. Rahman A, Grundke-Iqbal I, Iqbal K. Phosphothreonine-212 of Alzheimer abnormally
- 548 hyperphosphorylated tau is a preferred substrate of protein phosphatase-1. Neurochem
- 549 Res. 2005 Feb;30(2):277–87.
- 550 27. Alcolea D, Clarimón J, Carmona-Iragui M, Illán-Gala I, Morenas-Rodríguez E, Barroeta I,
- 551 et al. The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for
- biomarker discovery and validation in neurodegenerative disorders. Alzheimers Dement

553 N Y N. 2019;5:597–609.

28. Alcolea D, Pegueroles J, Muñoz L, Camacho V, López-Mora D, Fernández-León A, et al.

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse.

- 556 Ann Clin Transl Neurol. 2019 Sep;6(9):1815–24.
- 557 29. Iulita MF, Garzón Chavez D, Klitgaard Christensen M, Valle Tamayo N, Plana-Ripoll O,
- 558 Rasmussen SA, et al. Association of Alzheimer Disease With Life Expectancy in People


559 With Down Syndrome. JAMA Netw Open. 2022 May 23;5(5):e2212910.

- 30. Montoliu-Gaya L, Alcolea D, Ashton NJ, Pegueroles J, Levin J, Bosch B, et al. Plasma
 and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome:
 a longitudinal cohort study. eBioMedicine. 2023 Mar 30;90:104547.
- 563 31. Janelidze S, Christian BT, Price J, Laymon C, Schupf N, Klunk WE, et al. Detection of
- Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. JAMA Neurol. 2022
 Aug 1;79(8):797–807.

566 32. Lleó A, Zetterberg H, Pegueroles J, Karikari TK, Carmona-Iragui M, Ashton I


- 567 Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in
- adults with Down syndrome. Nat Commun. 2021 Jul 14;12(1):4304.
- 33. Lott IT, Head E. Dementia in Down syndrome: unique insights for Alzheimer disease
- 570 research. Nat Rev Neurol. 2019 Mar;15(3):135–47.
- 571 34. Deboever E, Fistrovich A, Hulme C, Dunckley T. The Omnipresence of DYRK1A in
- 572 Human Diseases. Int J Mol Sci. 2022 Aug 19;23(16):9355.
- 573 35. Murphy AJ, Wilton SD, Aung-Htut MT, McIntosh CS. Down syndrome and DYRK1A
- 574 overexpression: relationships and future therapeutic directions. Front Mol Neurosci. 2024
- 575 Jul 24;17:1391564.
- 36. De la Torre R, De Sola S, Pons M, Duchon A, de Lagran MM, Farré M, et al.
- 577 Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down
- 578 syndrome mouse models and in humans. Mol Nutr Food Res. 2014 Feb;58(2):278–88.
- 579 37. Chen H, Gao X, Li X, Yu C, Liu W, Qiu J, et al. Discovery of ZJCK-6-46: A Potent,
- 580 Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated
- 581 Kinase 1A Inhibitor for the Treatment of Alzheimer's Disease. J Med Chem. 2024 Aug
- 582 8;67(15):12571–600.


Α



P-tau181 Spearman Correlation


r=0.6602 (95% Cl 0.5185 - 0.7666)-O- Euploid groups r=0.6807 (95% Cl 0.3882 - 0.8486)-O- DS groups






Α

Β








С

Amyloid – (Euploid) vs. Amyloid + (Euploid)





20

15

Α

-35

-30

-25

-20

-15

-10

-5

Estimated Years to Onset (years)

Ò.

5

Table 1. Study Participants

	aDS	pDS	dDS	CN	MCI-AD	AD
n=	36/56	5/3	8/9	31/15	35/27	12/8
Female/Male	(39.1/60.9%)	(62.5/37.5%)	(47.1/52.9%)	(67.4/32.6%)	(56.5/43.5%)	(60/40%)
AGE (years)-range	18-62	41-60	46-59	18-75	56-83	53-83
AGE (years)-mean(sd)	42.2 (9.78)	51.5 (7.41)	51.8 (3.75)	50 (14.8)	72.3 (6.03)	70.5 (8.94)
AGE (years)-median[IQR]	44 [35.8-49]	52 [46.2-57]	52 [49-55]	46.5 [39-63.8]	72 [68-76.8]	71 [64.8-77.5]
	68/23	7/1	13/4	39/7	24/37	10/10
APOE4-/APOE4+	(74.7/25.3%)	(87.5/12.5%)	(76.5/23.5%)	(84.8/15.2%)	(39.3/60.7%)	(50/50%)
Plasma p-tau212 n	92	8	17	46	62	20
Plasma p-tau212 range	0.0435-1.69	0.666-2	0.404-2	0.0163-0.444	0.079-1.65	0.174-1.23
Plasma p-tau212 mean						
(SD)	0.404 (0.377)	1.11 (0.445)	0.929 (0.46)	0.166 (0.0856)	0.498 (0.28)	0.629 (0.29)
Plasma p-tau212	0.245	0.926 [0.831-	0.764	0.151	0.427	0.65
median[IQR]	[0.156-0.529]	1.24]	[0.627-1.23]	[0.113-0.235]	[0.33-0.632]	[0.372-0.738]
Plasma p-tau181 range	3.34-47.8	17-50.1	13.5-42.9	3.95-41.6	4.97-53.7	11.4-37.8
Plasma p-tau181 mean						
(SD)	15.9 (10.9)	29 (11.8)	23.5 (8.18)	11.1 (7.03)	22.3 (11.5)	22.6 (7.01)
Plasma p-tau181	11.7	24.7	21.6	9.02	19.3	22.5
median[IQR]	[7.54-20.9]	[20.4-35.3]	[18.9-27.7]	[7.07-12.7]	[14.6-27.9]	[18.2-27.4]
Total CAMCOG-DS score-						
n	73	3	12	0	0	0
Total CAMCOG-DS score-						
range	25-102	6-56	32-77	-	-	-
Total CAMCOG-DS score-						
mean(sd)	70.7 (20)	37.7 (27.5)	49.8 (13)	-	-	-
Total CAMCOG-DS score-						
median[IQR]	74 [57-87]	51 [28.5-53.5]	52 [38.5-57.2]			

aDS – asymptomatic Down syndrome; pDS – prodromal Down syndrome; dDS – dementia Down syndrome; CN – cognitively normal; MCI-AD – mild cognitive impairment due to Alzheimer's Disease; AD – Alzheimer's disease dementia; IQR – interquartile range; SD – standard deviation. CAMCOG-DS The Cambridge Cognitive Examination adapted for individuals with Down Syndrome